Stifel Downgrades Celator Pharmaceuticals (CPXX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Jazz Pharma (JAZZ) Confirms Agreement to Acquire Celator Pharma (CPXX) for $30.25/Share, or ~$1.5B
May 31, 2016 5:53 AM EDTJazz Pharmaceuticals plc (Nasdaq: JAZZ) and Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire Celator for $30.25 per share in cash, or approximately $1.5 billion.
The transaction with Celator is well-suited to advance Jazz Pharmaceuticals' growth strategy.
VYXEOS is the first product candidate to demonstrate a statistically significant improvement in Overall Survival in patients with high-risk (secondary) AML1U.S.... MoreCelator Pharma (CPXX) Near Deal to be Acquired by Jazz Pharma (JAZZ) - WSJ
May 30, 2016 10:44 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) is near a deal to acquire Celator Pharmaceuticals (NASDAQ: CPXX) for about $1.5 billion, the Wall Street Journal reported late Monday citing people familiar with the matter.
A deal for Celator,... More
